Comparing of Coherus BioSciences Inc. (CHRS) and uniQure N.V. (NASDAQ:QURE)

Coherus BioSciences Inc. (NASDAQ:CHRS) and uniQure N.V. (NASDAQ:QURE) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. N/A 0.00 209.34M -3.13 0.00
uniQure N.V. 11.28M 214.42 83.30M -2.69 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Coherus BioSciences Inc. and uniQure N.V.


Table 2 provides Coherus BioSciences Inc. and uniQure N.V.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. 0.00% -742.4% -126.3%
uniQure N.V. -738.48% -58.5% -35.9%

Risk and Volatility

Coherus BioSciences Inc. has a beta of 3.63 and its 263.00% more volatile than S&P 500. uniQure N.V.?s 7.00% more volatile than S&P 500 volatility due to the company’s 1.07 beta.


Coherus BioSciences Inc.?s Current Ratio and Quick Ratio are 5.3 and 5.3 respectively. The Current Ratio and Quick Ratio of its competitor uniQure N.V. are 7.6 and 7.6 respectively. uniQure N.V. therefore has a better chance of paying off short and long-term obligations compared to Coherus BioSciences Inc.

Analyst Recommendations

Ratings and Recommendations for Coherus BioSciences Inc. and uniQure N.V. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 2 3.00
uniQure N.V. 0 0 7 3.00

Coherus BioSciences Inc. has an average price target of $25, and a 68.46% upside potential. On the other hand, uniQure N.V.?s potential upside is 13.92% and its average price target is $74. The information presented earlier suggests that Coherus BioSciences Inc. looks more robust than uniQure N.V. as far as analyst opinion.

Institutional & Insider Ownership

Institutional investors owned 98.8% of Coherus BioSciences Inc. shares and 78.9% of uniQure N.V. shares. About 0.4% of Coherus BioSciences Inc.’s share are owned by insiders. Comparatively, uniQure N.V. has 2.2% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. 1.49% 11.66% 36.64% -25.41% 53.37% 66.08%
uniQure N.V. 6.3% 73.4% 107.66% 40.7% 137.94% 106.07%

For the past year Coherus BioSciences Inc. has weaker performance than uniQure N.V.


uniQure N.V. beats on 8 of the 10 factors Coherus BioSciences Inc.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.